A phase II clinical trial of the CDK 4/6 inhibitor palbociclib (PD 0332991) in previously treated, advanced non-small cell lung cancer (NSCLC) patients with inactivated CDKN2A.
2014 ◽
Vol 32
(15_suppl)
◽
pp. 8077-8077
◽
Keyword(s):
Phase Ii
◽